Our federal lawmakers should substantial and sustained investments for Alzheimer’s research funding and the dementia public ...

To no great surprise, the U.K.’s health technology assessment body has found that the benefits of the first two approved ...

To no great surprise, the U.K.’s health technology assessment body has found that the benefits of the first two approved Alzheimer’s disease drugs are too small to justify the costs. Neither Kisunla ...

The agency maintains that the beta-amyloid-targeting drugs show too limited benefit to justify their cost to the National Health Service.

A newly approved Alzheimer’s drug is set to be administered for the first time in Taiwan on Monday, Far Eastern Memorial Hospital in New Taipei City announced yesterday. Kisunla, the brand name of the ...

In a first for the bloc, Europe’s Committee for Medicinal Products for Human Use (CHMP) has recommended marketing ...

And more pharma news updates from Pharmalittle.

Jim Rogers, 58, was living and working in Australia when he started to develop symptoms of the incurable neurological ...

Eli Lilly (NYSE:LLY) announced it would appeal a decision by the U.K. health authorities not to recommend the company’s new ...

Jim Rogers said he first started noticing symptoms about two years before he was officially diagnosed with dementia at the ...

The re-examination of donanemab, marketed as Kisunla, began on June 2 following a request from Eli Lilly, according to the committee’s monthly meeting highlights on Friday. The committee had ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.